ClinicalTrials.gg
CompletedNCT00789321Updated Aug 11, 2015Results posted

A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)

A Phase 1 interventional study of Comparator: amlodipine besylate and Comparator: Placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
155th of 186
47 · median 180
Started
2008
with 13 others
Phase 1
17 of 187
none open now
Registered
68th of 187
by date
Lead sponsor
3 of 187
Merck Sharp & Dohme LLC

Among the 187 studies testing amlodipine in Hypertension, this one is the 155th largest by enrollment of the 186 interventional ones that give a count, is one of 14 that started in 2008, is one of 17 in phase 1, and was the 68th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

This study will evaluate methodologies for measuring pedal edema associated with calcium channel blockers in middle-aged and elderly subjects and patients with hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient does not have hypertension or has Stage I or II hypertension and is taking \< 3 anti-hypertension medications
  • Patient is willing to discontinue all anti-hypertensive medications during study
  • Patient is willing to refrain from drinking alcohol for 24 hours prior to each study visit and is willing to limit intake at other times during the study to 2 drinks per day
  • Patient agrees to avoid caffeine for 24 hours prior to each study visit. At other times during study, daily caffeine intake should not exceed 4 cups of coffee (or equivalent)
  • Patient will avoid strenuous physical activity during study
  • Patient is a nonsmoker or has not smoked for the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Patient has metal implants in the leg or artificial limbs
  • Patient has had a lower limb amputation, malformation, alterations in leg muscles, or a history of musculoskeletal disease
  • Patient has used oral pills or hormone replacement therapy within 3 months of screening
  • Patient has a history of stroke or seizures
  • Patient has a history of cancer, except that which was treated at least 10 years prior to screening and shows no evidence of recurrence
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    1

    amlodipine

    Drug: Comparator: amlodipine besylate

  • Placebo comparator
    2

    Placebo to amlodipine

    Drug: Comparator: Placebo

Interventions

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two 5 mg tablets amlodipine daily for 6 weeks.

  • DrugComparator: Placebo

    Two 5 mg tablets placebo to amlodipine daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2

    Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint.

    Time frame: Baseline and 2 weeks

Secondary outcomes

  1. Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2

    Least Squares Mean Difference from Baseline

    Time frame: Baseline and 2 weeks

07

Results

Posted Jul 8, 2010

Participant flow

Participants were recruited across 3 Phase I clinical research units in the US. Participants participated from July 2008 to March 2009.

Participant flow — Overall Study
MilestoneAmlodipine 10 MilligramsPlacebo
Started2423
Completed2422
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryChange From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2

Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint.

Time frame:
Baseline and 2 weeks
Reported as:
Least squares mean · Ohms
Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2
OhmsAmlodipine 10 MilligramsPlacebo
Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2-7.9 ± 20.73.8 ± 17.0
Statistical analysis
  • Amlodipine 10 Milligrams vs Placebo · ANCOVA · p = 0.001 · Least squares mean: -11.7 · 90% CI -18.1 to -5.4Change from baseline in systolic blood pressure included as covariate
SecondaryChange From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2

Least Squares Mean Difference from Baseline

Time frame:
Baseline and 2 weeks
Reported as:
Least squares mean · Grams
Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2
GramsAmlodipine 10 MilligramsPlacebo
Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 244.8 ± 64.85.8 ± 53.2
Statistical analysis
  • Amlodipine 10 Milligrams vs Placebo · ANCOVA · p = 0.001 · Least squares mean: 39.0 · 95% CI 17.9 to 60.1Change from baseline in systolic blood pressure included as covariate

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine 10 Milligrams—0/24 (0%)17/24 (70.8%)
Placebo—0/23 (0%)16/23 (69.6%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventAmlodipine 10 MilligramsPlacebo
Oedema PeripheralGeneral disorders12/249/23
Accidental OverdoseInjury, poisoning and procedural complications3/242/23
Tension HeadacheNervous system disorders1/242/23
NauseaGastrointestinal disorders1/241/23
VomitingGastrointestinal disorders0/241/23
InflammationGeneral disorders0/241/23
Viral InfectionInfections and infestations0/241/23
Muscle SpasmsMusculoskeletal and connective tissue disorders1/241/23
HeadacheNervous system disorders0/241/23
PalpitationsCardiac disorders1/240/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Amlodipine 10 MilligramsPlaceboTotal
Mean58.4 ± 5.659.6 ± 6.259.0 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine 10 MilligramsPlaceboTotal
Female131124
Male111223
Body Mass Index
Body Mass Index(kg/m^2)Amlodipine 10 MilligramsPlaceboTotal
Mean28.2 ± 2.929.0 ± 2.728.6 ± 2.8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Schoeller DA, Alon A, Manekas D, Mixson LA, Lasseter KC, Noonan GP, Bolognese JA, Heymsfield SB, Beals CR, Nunes I. Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study. Clin Ther. 2012 Mar;34(3):580-92. doi: 10.1016/j.clinthera.2012.01.018. Epub 2012 Mar 3. PubMed 22385927 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2008
First posted
Nov 11, 2008
Start
Jul 2008
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Results first posted
Jul 8, 2010
Last update
Aug 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00789321
Responsible party
Sponsor
First posted
Nov 11, 2008
Start date
Jul 2008
Primary completion
Feb 2009
Completion
Mar 2009
Results posted
Jul 8, 2010
Last update
Aug 11, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion